Stock Updates

Is this Large Market Cap Stock target price reasonable for Neurocrine Biosciences Inc. (NASDAQ:NBIX)?

The company in question is, Neurocrine Biosciences Inc. (NASDAQ:NBIX) currently with a stock price of 43.03 (-2.55% today). The market cap for Neurocrine Biosciences Inc. is 3879.01, and is in the sector Healthcare, and Drugs РGeneric industry. The target price for Neurocrine Biosciences Inc. is 70.5. Currently Neurocrine Biosciences Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Neurocrine Biosciences Inc. is 750.58 and so far today it is 236463.

Performance in the last year for Neurocrine Biosciences Inc. has been -1.01%. For EPS growth, Neurocrine Biosciences Inc. has seen a growth of -29.60%, and is looking to grow in the next year to -1.60%. More long term stats show that EPS growth has been -47.50% over the last five years and could be -9.18% for the next five years. Neurocrine Biosciences Inc. has seen sales growth quarter over quarter at *TBA, with EPS growth quarter over quarter at -65.60%. The 20-day simple moving average is -13.81%, with the 200-day simple moving average coming to -5.34%.

Since the IPO date for Neurocrine Biosciences Inc. on the 5/23/1996, Neurocrine Biosciences Inc. has seen performance year to date to be -21.94%. With Neurocrine Biosciences Inc. trading at 43.03, the dividend yield is *TBA, and the EPS is -1.43.

So could Neurocrine Biosciences Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 258.6 and the P/B is at 10.04. The P/cash is 10.01, with P/free cash flow at *TBA.

Neurocrine Biosciences Inc. ability to deal with debt shows that the current ratio is 14.6, and the quick ratio is 14.6. This is with long term debt/equity at 0, and total debt/equity at 0.

In terms of margins, Neurocrine Biosciences Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Neurocrine Biosciences Inc. is *TBA. Return on assets come to -26.60% with return on investment coming to -22.20%.

Insider ownership for Neurocrine Biosciences Inc., is at 0.50% and institutional ownership comes to 98.10%. Outstanding shares are at 87.84. While shares float is 85.72. The float short is currently 5.86%, and short ratio is 6.69.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment